A shareholder probe is examining whether Generation Bio’s deal with XOMA Royalty unfairly favored insiders and harmed shareholder value.

The Ademi Firm is investigating Generation Bio’s $4.2913 per share deal with XOMA Royalty Corp., focusing on whether the board upheld fiduciary duties. Shareholders get cash and a CVR tied to future payments from net cash, lease savings, and Moderna royalties. The probe examines if change-of-control perks for insiders and a penalty for accepting better offers unfairly limit shareholder value. The firm is assessing potential breaches of law and governance standards, offering free inquiries for affected investors.